Altimmune, Inc. (ALT)
Chart Events
Performance Outlook
| Previous Close | 5.1600 |
| Open | 5.1100 |
| Bid | 4.8400 x 1400 |
| Ask | 4.8500 x 1000 |
| Day's Range | 4.8100 - 5.1700 |
| 52 Week Range | 3.8300 - 19.4600 |
| Volume | |
| Avg. Volume | 869,651 |
| Market Cap | 193.13M |
| Beta (5Y Monthly) | 1.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1100 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 20, 2017 |
| 1y Target Est | 31.67 |
- GlobeNewswire
Altimmune to Present at Upcoming Investor Conferences
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022: H.C. Wainwright Global Investment ConferenceTuesday, May 24, 20227:00 am Eastern TimeThe session will be webcast and can be accessed by visiting the Events section of the Altimmune website. B. Riley Securities Institutional Investor Conference
- Simply Wall St.
Altimmune (NASDAQ:ALT) surges 19% this week, taking three-year gains to 111%
The last three months have been tough on Altimmune, Inc. ( NASDAQ:ALT ) shareholders, who have seen the share price...
- GlobeNewswire
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
Multiple clinical trial data readouts expected in Q3 and Q4 2022GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2022 and provided a corporate update. “We continue to advance the development of pemvidutide, our GLP-1/Glucagon dual receptor agonist and look forward to reporting both weight loss and liver fat reduction data from multiple ongoing clini
